THE ALLIANCE NCTN BIOREPOSITORY AND BIOSPECIMEN RESOURCE

NCTN 生物样本库和生物样本资源联盟

基本信息

批准号：
9070651
负责人：
MICHAEL A CALIGIURI
金额：
$ 222.85万
依托单位：
WASHINGTON UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-05-19 至 2020-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9070651
关键词：
Advanced Malignant Neoplasm Affect American College of Surgeons Oncology Group Automobile Driving Biological Biological Assay Biological Markers Cancer Control Cancer Diagnostics Cancer and Leukemia Group B Clinical Clinical Research Clinical Treatment Clinical Trials Clinical Trials Network Collection Communities Community Clinical Oncology Program Companions Data Eligibility Determination Enrollment Equipment and supply inventories Funding Future Genomics Health Informatics Investigational Therapies Laboratories Leadership Liquid substance Malignant Neoplasms Methods Mission National Clinical Trials Network North Central Cancer Treatment Group Pathology Patients Prevention trial Procedures Process Proteomics Quality Control Research Research Infrastructure Resources Science Services Site Speed Stratification The Cancer Genome Atlas Therapeutic Clinical Trial Therapeutic Trials Time Tissues Translational Research Translations Validation Work anticancer research base biobank biomarker development cancer clinical trial candidate marker clinical practice cohort community setting control trial cost improved innovation meetings member minimally invasive multidisciplinary new technology novel oncology operation programs quality assurance targeted treatment tool treatment trial trial design validation studies

项目摘要

DESCRIPTION (provided by applicant): The NCTN's Alliance for Clinical Trials in Oncology (Alliance) represents a merger of three former NCI-funded cancer cooperative groups (ACOSOG, CALGB, and NCCTG). Combined, these groups and their associated biorepositories represent an unequaled resource of expertise, institutional infrastructure, and high quality, densely annotated patient biospecimens collected from several decades of cancer therapeutic trials. The scientific mission of the Alliance Biorepository and Biospecimen Resource (ABBR) is to support the activities of the Alliance, the NCTN, and the broader cancer research community through four specific aims, which are: 1) To prospectively support Alliance and NCTN-wide clinical cancer trials with respect to biospecimen procurement, tracking, processing, quality assurance, storage, and distribution. The ABBR will develop approaches to streamline biospecimen collection and support the collection of novel biospecimen types for genomic- and proteomic-based biomarker studies in the context of therapeutic trials; 2) To provide a resource of high quality, densely annotated biospecimens for secondary correlative science studies directed toward biomarker validation with high clinical impact. The ABBR will work with other NCTN biorepositories, the NCTN Biospecimen `Front Door Service', and the NCTN Navigator tool to provide inventories of biospecimens that may be suitable for secondary correlative science studies proposed both within the NCTN groups as well as the broader cancer research community. It will also work with other NCTN members and NCI to create an efficient and transparent process for reviewing, approving, and executing such requests so as to speed the translation of candidate biomarkers to cancer diagnostics with clinical utility; 3) To provide scientific leadership to the NCTN biobanking enterprise, by active participation in the NCTN Group Banking Committee (GBC). The ABBR will continue its outstanding commitment to harmonizing and improving biobanking Best Practices by active participation in GBC meetings, subcommittee's activities, and work products, and; 4) To provide expertise and infrastructure support for biobanking efforts beyond the NCTN, including NCI's Experimental Therapeutics Clinical Trials Network (ETCTN) and the Community Oncology Research Program (NCORP). By creating a federated infrastructure of biorepository sites and a unifying informatics platform for tracking biospecimens across them, the ABBR is uniquely poised to collaborate with other NCI programs, whenever biorepository or biospecimen resources are required for specific translational cancer research efforts.

描述（由申请人提供）： NCTN 肿瘤学临床试验联盟（联盟）代表了三个前 NCI 资助的癌症合作组织（ACOSOG、CALGB 和 NCCTG）的合并，这些组织及其相关的生物样本库代表了无与伦比的地位。联盟的科学使命是从数十年的癌症治疗试验中收集的专业知识资源、机构基础设施以及高质量、详细注释的患者生物样本。生物样本库和生物样本资源 (ABBR) 旨在通过四个具体目标支持联盟、NCTN 和更广泛的癌症研究界的活动，这些目标是： 1) 前瞻性地支持联盟和 NCTN 范围内有关生物样本的临床癌症试验ABBR 将开发简化生物样本收集的方法，并支持在治疗背景下收集用于基于基因组和蛋白质组的生物标志物研究的新型生物样本。试验；2) 为具有高临床影响的生物标志物验证的二级相关科学研究提供高质量、详细注释的生物样本资源。导航器工具提供生物样本清单，可能适合 NCTN 小组以及更广泛的癌症研究界提出的二级相关科学研究，它也将与其他机构合作。 NCTN 成员和 NCI 创建高效、透明的流程来审查、批准和执行此类请求，以加快将候选生物标志物转化为具有临床实用性的癌症诊断；3) 通过积极主动地为 NCTN 生物样本库企业提供科学领导；参与 NCTN 集团银行委员会 (GBC)，ABBR 将继续积极参与 GBC 会议、小组委员会的活动和工作成果，以协调和改进生物样本库最佳实践； 4) 通过创建生物样本库站点的联合基础设施和统一的跟踪信息学平台，为 NCTN 以外的生物样本库工作提供专业知识和基础设施支持，包括 NCI 的实验治疗临床试验网络 (ETCTN) 和社区肿瘤学研究计划 (NCORP)。每当特定的转化癌症研究需要生物样本库或生物样本资源时，ABBR 都准备好与其他 NCI 项目合作努力。